Evidence map›Paper›PMID 39598371›Full record

ArticlePharmaceuticals (Basel, Switzerland)2024

Different PSMA Radiopharmaceuticals: A Comparative Study of [

Zsófia Sára Mikó, László Varga, István Farkas, Gyula Tóth, Kristóf Apró, Barnabás Márk Révész, Gábor Sipka, Péter Gergő Tompa, Annamária Bakos, Tamás Czékus and 5 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Pharmaceuticals (Basel, Switzerland), 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors.

Zsófia Sára MikóDepartment of Nuclear Medicine, University of Szeged, 6720 Szeged, Hungary.
László VargaDepartment of Nuclear Medicine, University of Szeged, 6720 Szeged, Hungary.ORCID 0009-0008-5223-2053
István FarkasDepartment of Nuclear Medicine, University of Szeged, 6720 Szeged, Hungary.
Gyula TóthPozitron Diagnosztika Ltd., 1117 Budapest, Hungary.
Kristóf ApróDepartment of Nuclear Medicine, University of Szeged, 6720 Szeged, Hungary.
Barnabás Márk RévészDepartment of Nuclear Medicine, University of Szeged, 6720 Szeged, Hungary.
Gábor SipkaDepartment of Nuclear Medicine, University of Szeged, 6720 Szeged, Hungary.
Péter Gergő TompaDepartment of Nuclear Medicine, University of Szeged, 6720 Szeged, Hungary.
Annamária BakosDepartment of Nuclear Medicine, University of Szeged, 6720 Szeged, Hungary.
Tamás CzékusDepartment of Nuclear Medicine, University of Szeged, 6720 Szeged, Hungary.
Mátyás BukvaDepartment of Immunology, University of Szeged, 6720 Szeged, Hungary.
László PávicsDepartment of Nuclear Medicine, University of Szeged, 6720 Szeged, Hungary.
Linda VargaDepartment of Oncotherapy, University of Szeged, 6720 Szeged, Hungary.
Anikó MarázDepartment of Oncotherapy, University of Szeged, 6720 Szeged, Hungary.ORCID 0000-0002-2018-8413
Zsuzsanna BesenyiDepartment of Nuclear Medicine, University of Szeged, 6720 Szeged, Hungary.ORCID 0000-0001-9115-9620

Funding

National Research, Development and Innovation Office, Hungary 2019-1.1.1-PIACI-KFI-2019-00194
6 · The paper itself

Abstract

backgroundNumerous PSMA-based tracers are used for diagnostic prostate cancer imaging, but comprehensive comparisons between multiple ligands are lacking. This study aimed to compare physiological skeletal uptake and tracer uptake in commonly recommended PSMA reference regions across three different PSMA ligands in prostate cancer patients.

methodsA total of 281 prostate cancer patients were included. Using PET and SPECT imaging, target volumes of interest were defined via a semiautomatic method, and standardized uptake values (SUV) were calculated for the skeletal system and reference regions (liver, spleen, parotid gland, and blood pool).

resultsSignificant differences in SUV uptake were observed, with [

conclusionsWhile radioligands behave similarly in bone regions, there are notable differences in SUV patterns, particularly for PSMA-1007, which showed higher bone uptake. Parotid gland uptake variability suggests a reconsideration of its suitability as a reference region, while the liver, spleen, and blood pool showed more consistent uptake. During comparison, the technetium-labeled SPECT ligand proved as similarly effective as the two PET ligands for diagnostic imaging.

Indexed as

JK-PSMA-7PETPSMAPSMA-1007radiopharmaceuticalSPECTTc-PSMA I&SUBU (unknown bone uptake)

Identifiers

PMID39598371
PMCPMC11597438

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.